Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.
about
"Stormy waters ahead": global emergence of carbapenemasesFosfomycin: A First-Line Oral Therapy for Acute Uncomplicated CystitisResistance to antibiotics targeted to the bacterial cell wallGenome-Wide Identification of Antimicrobial Intrinsic Resistance Determinants in Staphylococcus aureusThe global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignanciesFosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany.Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012.Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomesF33: A-: B-, IncHI2/ST3, and IncI1/ST71 plasmids drive the dissemination of fosA3 and bla CTX-M-55/-14/-65 in Escherichia coli from chickens in China.Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolatesFosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis - an observational study.Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.Molecular Basis for Resistance Against Phosphonate Antibiotics and Herbicides.FosfomycinUncomplicated Urinary Tract Infections and Antibiotic Resistance-Epidemiological and Mechanistic AspectsMultidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum β-lactamase producing strains.Carbapenem-Resistant Enterobacteriaceae Infections in Children.Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination TherapyIn Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.Combating multidrug-resistant Gram-negative bacterial infections.Treatment of multidrug-resistant Gram-negative infections in children.Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.Tackling antimicrobial resistance in lower urinary tract infections: treatment options.Fosfomycin: Mechanism and Resistance.Antimicrobial treatment of serious gram-negative infections in newborns.Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study.Intravenous Fosfomycin for the treatment of hospitalized patients with serious infections.Mechanism of Reduced Susceptibility to Fosfomycin in Escherichia coli Clinical Isolates.Whole-Genome Analysis of Antimicrobial-Resistant and Extraintestinal Pathogenic Escherichia coli in River Water.Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges.Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
P2860
Q21131125-B9124961-2853-4F26-BAE5-EC7C6597AFD6Q26745740-54EE492E-EC34-4D9E-8775-FD4CFA865A6AQ26859841-4F4E54F9-201D-4882-8650-CAED77E6167EQ28354064-D7AC0CBF-3C6B-4729-A833-250B11AD9C7EQ33686940-A399A222-6B31-4539-9B5D-03EC37E129E1Q33703401-A70A4F2E-ACD9-4A3D-B079-43C29DE3303CQ33732529-0944CFAF-0999-421E-8509-519DA585E0EEQ34320945-8CB84F78-58A0-4321-91D2-77A17C70666FQ34709726-96B43A5D-4766-467F-BA74-C98EC264DEE6Q34921154-B629DAA6-6358-4E77-8E85-EC9A63FE5CB4Q35076855-60088A7F-D052-4526-8167-CCF1B7E798E2Q35278325-B90DF22F-9A4B-4908-83E9-B9DC9493494BQ35960788-75C81933-9C14-4100-981F-7BECCCD5D839Q35966554-3BF9510D-7F8B-4C82-BF78-D6D45EBCE47FQ36160749-62A32992-8BE7-41D2-B066-2F66902F0CAAQ36290521-1A4EA303-21AD-4730-B471-833FD24BE6D6Q36490822-5A4A4C97-A905-46D7-8720-0AE5A2A2B6F3Q36675246-C0801926-90C4-414E-A9A6-728CEEB1DD98Q36683661-BCD4C42A-E1BB-4C49-A0F8-B53453095B1AQ36761826-C7C792DA-C6FC-490B-9EF1-D829561118FFQ37001229-9091D4A4-43BE-4DDC-9A3C-CA8DA0A7048DQ37154718-4F81C98F-87F0-4837-8095-F07C9EED7F7FQ37538644-6D6317DA-C54A-429D-898A-831CD3111603Q37544647-B1589406-CB3C-4511-BD10-0BFEEDFF9148Q38160759-7756447B-B2A0-491D-A99F-2548C30993CEQ38161570-610BBFA7-9CFC-478A-83F3-1FF3CDCC949BQ38185648-8E9FDF26-2DAF-42F9-B4F1-AB3834AE6431Q38208281-12C0C08B-8179-4532-BF8C-267A4D1AEEA7Q38325217-56DE0A98-3BD1-4840-9371-650E9D04AE8AQ38689344-1C114A9B-100E-45D8-A467-61744BE99EA9Q38833839-AA397F78-BAE5-4E53-BBC5-5E88A0A2A332Q39071416-3B4BD908-4DE5-438F-88D8-94340B02CA8CQ39249188-B8D0B40E-0AE3-4770-8711-7EFA570E35EFQ39425303-72BC796B-086A-46CF-A8DC-61296D6741DDQ40049542-015914E6-1AFF-4F92-B368-93EEE9A8D430Q40333130-0A2A6A6B-518A-49EF-9268-D56A3FB6DB5EQ40406138-4DE28A72-FAAF-4ADE-B5D5-C421BE6FD727Q40422166-1CCCE46B-4359-4888-989F-C1411600B392Q40499211-F517073C-8685-423E-B00C-C3E0C29D37C4Q40697349-D4AD7B9B-DAEE-4A50-A3B8-ED3D41D4570E
P2860
Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Fosfomycin: evaluation of the ...... ce in Gram-negative pathogens.
@en
Fosfomycin: evaluation of the ...... ce in Gram-negative pathogens.
@nl
type
label
Fosfomycin: evaluation of the ...... ce in Gram-negative pathogens.
@en
Fosfomycin: evaluation of the ...... ce in Gram-negative pathogens.
@nl
prefLabel
Fosfomycin: evaluation of the ...... ce in Gram-negative pathogens.
@en
Fosfomycin: evaluation of the ...... ce in Gram-negative pathogens.
@nl
P2860
P356
P1476
Fosfomycin: evaluation of the ...... nce in Gram-negative pathogens
@en
P2093
P2860
P304
P356
10.1093/JAC/DKR466
P407
P577
2011-11-16T00:00:00Z